Precision Oncology specialist, Alex Rolland, discusses a new FGFR inhibitor which has been recently FDA-approved (January 2024) for locally advanced or metastatic urothelial carcinoma with FGFR3 genetic alterations in patients whose disease has progressed on, or after, at least one line of prior systemic therapy.
He explains the results of the study that prompted this approval and the key takeaways that patients need to know in order to get the most benefit from this new drug approval.
He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that Urothelial cancer patients need to know about this new treatment - including next steps you can take to find out if it will work for you and how to access it.
00:00 Introduction
00:16 Alex’s Presentation: Targeting FGFR Alterations In Advanced Urothelial Cancer
01:06 What is FGFR? (Fibroblast Growth Factor Receptor 3)
04:04 Visual representation of how FGFR3 works
04:50 What happens when FGFR3 becomes mutated
07:05 The ten cancer types that FGFR alterations are found in
07:52 New FDA-Approval for FGFR inhibitor “Erdafitinib”
09:39 Exploring the results of the THOR Trial
11:03 Comparing the Median Overall Survival rates: Erdafitinib vs. chemo
11:42 Comparing the side effects: Erdafitinib vs. chemo
13:00 Which tests a patient needs to find out if this new treatment will benefit them
14:28 Next steps patients can take to get more information and support
Read more about the BLC3001 (THOR) Trial and the FDA approval of this drug:
www.nejm.org/doi/full/10.1056...
Learn more about the tumour testing required to match you to this treatment: • Why Tumor DNA Sequenci...
If you’d like to identify the most effective treatment for your cancer, and how to access it as soon as possible (and through your current treatment team) reach out to us and book a free 30-min consult using the link below 👇
Book a Free Session With Alex And His Precision Oncology Team: www.ctoam.com/free-strategy-s...
Download CTOAM’S Free Ebook Here: www.ctoam.com/ebook/
Join our (free) "Cancer Just the Facts" online program!
👉 cancerjustthefacts.com/
Get hundreds of free resources on Precision Cancer Medicine and access to our weekly Zoom calls with cancer experts.
-
CTOAM is a worldwide, Canadian-based personalized cancer care and precision oncology service specializing in getting our client's rapid access to the best possible cancer treatment available for their form of cancer, while assisting their physicians in having the most current data from which to make confident treatment decisions on your behalf.
We facilitate access to peer-reviewed, science-based precision diagnostics such as PET/CT scans, liquid biopsy (blood-based genetic tests) and detailed genetic panels. We use these leading diagnostic tools, combined with a thorough and personalized research review, as our team explores the most advanced scientific data available today to find the best options for you.
Other ways to stay in touch with CTOAM:
Facebook: / cancertreatmentoptions...
LinkedIn: / ctoam
Twitter: / ctoam
Blog: research.ctoam.com/
LinkedIn (Liquid Biopsy Labs): / 13063544
LBL Twitter: / liquidbiopsynow
Disclaimer:
Please understand that these videos are meant for educational purposes only. These videos are not intended to diagnose or be used as treatment advice. Viewers are encouraged to speak with their doctor or healthcare professionals for medical advice and before making any changes to their healthcare based on this information. All statements made in this video regarding medical treatments and health conditions are sourced and have been approved by the U.S. Food and Drug Administration (FDA). Watching this video is not a substitute for professional medical advice or a diagnosis.